Phion technology

RALA.png

RALA is a 30 amino acid peptide with the following advantages for precision drug delivery:

RALA nanoparticles have many advantages

High cell transfection / cellular entry without associated toxicity

Self-assembly with nucleic cargo, irrespective of size

Stable nanoparticle with no need for cold chain storage

Non-immunogenic nanoparticles facilitate repeated dosing

Protection of drug cargo while increasing circulatory half-life

Demonstrated formulation lyophilisation and easy scale up

RALA APPLICATIONS

RALA is optimised for both localised and systemic delivery, excelling in in vitro, in vivo and ex vivo applications.

 

RALA-V is an optimised RALA & triple-plasmid nanoparticle system for efficient and cost-effective production of AAV viral vectors for use in gene therapy applications

RALA.jpg
RALA-V.jpg
Publications.jpg

PUBLICATIONS

Over 20+ studies have been published using the RALA system, ranging from the fundamental design and application of an efficient cell penetrating peptide to use as a potential therapeutic mRNA vaccine candidate.

 

Below is a selection of publications of special note:

McCarthy HO et al. Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery.
J Control Release. 2014 Sep 10;189:141-9.
Udhayakumar VK et al. Arginine-Rich Peptide-Based mRNA Nanocomplexes Efficiently Instigate Cytotoxic T Cell Immunity Dependent on the Amphipathic Organization of the Peptide.
Adv Healthc Mater. 2017 Jul;6(13).
Ali AA et al. DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles.
Nanomedicine. 2017 Apr;13(3):921-932.
McCrudden CM et al. Systemic RALA/iNOS nanoparticles; a potent gene therapy for metastatic breast cancer coupled as a biomarker of treatment.
Mol Ther Nucleic Acids. 2017 Mar 17;6:249-258.
Cole G et al. Dissolving microneedles for DNA vaccination: improving functionality via polymer characterisation and RALA complexation.
Hum Vaccin Immunother. 2017 Jan 2;13(1):50-6.
Cole G et al. DNA vaccination for cervical cancer: Strategic optimisation of RALA mediated gene delivery from a biodegradable microneedle system.
Eur J Pharm Biopharm. 2018 Jun;127:288-297.
Cole G et al. DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen.
Acta Biomater. 2019 Sep 15;96:480-490.
Mulhulland EJ et al. Delivery of RALA/siFKBPL nanoparticles via electrospun bilayer nanofibres: An innovative angiogenic therapy for wound repair.
J Control Release. 2019 Dec 28;316:53-65.

Find Out More

© 2020 by pHion Therapeutics Ltd.

  • Twitter - White Circle
  • LinkedIn - White Circle